Pharma has really not participated in rallies. In the last couple days, we have started to see some movement, like Pfizer. It is an area that will eventually be discovered. There is decent growth, nice dividends, but it lacks excitement. Nice to have one or two. It could be one of them.
The cost of bringing a new drug to market hasn't changed, but the customer base has shrunk. Same costs, smaller revenue base. He likes healthcare for being recession-resistant, but he prefers a medical device company like Stryker.
GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N
In the last year, 5 stock analysts published opinions about GSK-N. 4 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for GlaxoSmithKline PLC.
GlaxoSmithKline PLC was recommended as a Top Pick by on . Read the latest stock experts ratings for GlaxoSmithKline PLC.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered GlaxoSmithKline PLC In the last year. It is a trending stock that is worth watching.
On 2022-06-24, GlaxoSmithKline PLC (GSK-N) stock closed at a price of $43.69.